Variant Summary
- Also known as
- RET Fusion
- HGVS
- —
- Variant Type(s)
- transcript_fusion
- Evidence Items
- 10
Evidence Level Distribution
Level A: 3Level B: 6Level C: 1
Evidence Items
Showing CIViC evidence rows where gene = v::RET and variant = Fusion.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Pralsetinib | 4 |
| A | Predictive | Supports | Sensitivity/Response | Thyroid Cancer | Pralsetinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Selpercatinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Papillary Thyroid Carcinoma | Selpercatinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Selpercatinib | 4 |
| A | Predictive | Supports | Sensitivity/Response | Thyroid Cancer | Selpercatinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Cabozantinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Vandetanib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Vandetanib | 3 |
| C | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Alectinib | 3 |